The case in front of me: early satiety · two · orforglipron.
I am trying to do this correctly the first time rather than learn it by getting it wrong.
I have already made one mistake here that cost me a vial, so I am being deliberately careful.
What is the correct sequence, and where is the step that people usually skip?
Week 2 is day 14: on a four-week ladder that is week 2 of dose step 1, and — at the seven-day half-life this class runs on — 2 half-lives in. Steady state is about five half-lives, so day 35 is where the concentration stops climbing on its own. Day 14 is 3 weeks short of it, so the level is still rising even though the dose has not changed. That distinction is most of the question: at week 2 of a step, an effect that is still accumulating is indistinguishable from one that is not resolving unless you know which side of day 35 you are on. Early satiety is the mechanism rather than a side effect of it — delayed gastric emptying is the intended pharmacology — so the question the week number helps with is whether it is proportionate, not whether it is expected. Dose decisions are made under supervision, and nothing here is medical advice.
Start with which symptom predominates, because the management diverges sharply even though the mechanism does not.
Symptom prevalence in trials, broadly: nausea a quarter to a half, diarrhoea and constipation each roughly ten to twenty per cent, vomiting rather less, with all rates rising with dose.
Reflux occurs because a slower-emptying stomach retains volume for longer against a lower oesophageal sphincter that has not changed. Smaller meals and not lying down within a few hours are the direct responses.
Trial-reported incidence and discontinuation rates for gastrointestinal effects are published per agent and per dose and are the appropriate figures to quote.
Smaller meals, less fat, fluids between rather than with. In that order.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsThis is the group of effects that drives almost all discontinuation in the trial programmes.
Fat is the macronutrient that slows emptying most on its own, so a high-fat meal on top of pharmacologically delayed emptying is the combination that produces the worst episodes.
Anticipating a slower-than-label titration from the start is a legitimate approach and costs only time, since the exposure ceiling is the same.
Four-weekly titration intervals in the licensed schedules were selected to allow tolerance between escalations.
Nothing here is medical advice.
Slow the titration first. It is the intervention with the best evidence and the lowest cost.
Diarrhoea and constipation both occur, which surprises people until they consider how many mechanisms are involved.
Discontinuation for gastrointestinal effects in the trials runs in the low single-figure percentages, which means the great majority of people who experience these effects continue.
Symptoms that appear for the first time at a stable dose after months are not the ordinary pattern and warrant looking for another explanation.
Symptoms appearing late at a stable dose deserve a differential diagnosis rather than an assumption.
Most people who report these effects continue. The discontinuation rate is low.
Reflux is the symptom people least expect and it follows directly from a stomach that empties slowly.
The practical hierarchy of interventions: slow the titration, reduce meal size, reduce fat, separate fluids from meals, and only then consider symptomatic treatment.
Gastric emptying studies in this class quantify the delay directly and document its attenuation with continued exposure to the long-acting agents.
New symptoms at a stable dose after months need a different explanation.
edited 29 Mar 2026 by w_okoye — added the citation requested in comments
Answer first: the gastrointestinal effects in this class share one mechanism — slowed gastric emptying plus central signalling — and present as nausea, fullness, reflux, constipation or diarrhoea depending on the person.
Gastric emptying of a solid meal can be delayed substantially at initiation. The effect is largest early and attenuates over weeks for the long-acting agents, which is the mechanistic basis for the titration schedule.
Everything except constipation attenuates. Plan differently for that one.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.